How should I diagnose and manage a patient with chronic obstructive pulmonary disease, including severity assessment, smoking cessation, vaccinations, pharmacologic therapy, pulmonary rehabilitation, and advanced treatment options?

COPD Diagnosis and Management

Diagnostic Confirmation

Confirm COPD diagnosis with post-bronchodilator spirometry showing FEV₁/FVC <0.70—this objective measurement is mandatory before initiating any therapy. 1, 2

• Suspect COPD in patients with smoking history (especially >40 pack-years), age >45 years, and symptoms of dyspnea, chronic cough, or wheezing 3
• Measure FEV₁ % predicted to classify severity: mild (≥80%), moderate (50-79%), severe (<50%) 1, 2
• Obtain chest radiograph to exclude lung cancer, pneumonia, and assess for cor pulmonale (right descending pulmonary artery >16mm suggests pulmonary hypertension) 2
• Measure arterial blood gases if FEV₁ <50% predicted or clinical signs of respiratory failure 4, 2
• Check alpha-1 antitrypsin level in patients <40 years or with atypical presentation 4, 2

---

Smoking Cessation: The Only Disease-Modifying Intervention

Implement high-intensity smoking cessation immediately using combination nicotine-replacement therapy (patch PLUS rapid-acting form like gum) together with either varenicline or bupropion, plus intensive behavioral counseling—this is the ONLY intervention proven to reduce mortality and slow disease progression. 1, 2

• Intensive counseling combined with pharmacotherapy yields sustained quit rates of 25% versus 3-5% with willpower alone 1
• Advise abrupt cessation rather than gradual reduction, as gradual withdrawal rarely achieves complete cessation 2
• Smoking cessation prevents accelerated FEV₁ decline but does not restore previously lost lung function 1, 5

---

Pharmacologic Therapy: Stepwise Algorithm

Mild COPD (FEV₁ ≥80% predicted)

Prescribe short-acting β₂-agonist (SABA) OR short-acting anticholinergic (SAMA) as needed for symptom relief. 1, 5

• No routine maintenance medication is required in asymptomatic patients 5
• Optimize inhaler technique at every visit—76% of patients make critical errors with metered-dose inhalers 1, 5

Moderate COPD (FEV₁ 50-79% predicted)

Initiate long-acting muscarinic antagonist (LAMA) monotherapy as first-line maintenance therapy (tiotropium 18 µg once daily, umeclidinium 62.5 µg once daily, or aclidinium 400 µg twice daily). 1, 5

• If LAMA is not tolerated, use long-acting β₂-agonist (LABA) monotherapy (salmeterol 50 µg twice daily or formoterol 12 µg twice daily) 1
• Consider a 2-week trial of oral prednisolone 30 mg daily with pre- and post-spirometry; a positive response requires FEV₁ increase ≥200 mL AND ≥15% of baseline—only 10-20% of patients meet this criterion 4, 1, 5

Severe COPD (FEV₁ <50% predicted)

Begin with fixed-dose combination LAMA + LABA as first-line therapy; dual bronchodilation reduces exacerbations by 13-17% compared with monotherapy. 1, 5

Add inhaled corticosteroid (ICS) ONLY if:

• FEV₁ <50% predicted AND ≥2 moderate exacerbations or ≥1 hospitalization in the prior year, OR 1, 5

• Blood eosinophil count ≥150-200 cells/µL, OR 1

• Documented asthma-COPD overlap 1

• Recommended ICS doses: fluticasone 250-500 µg twice daily or budesonide 320-400 µg twice daily 1

• If no recent exacerbations and normal eosinophil count, withdraw ICS—cessation has not been shown to cause significant harm 1

Additional Therapies for Persistent Exacerbations

• Roflumilast 500 µg once daily for patients with FEV₁ <50% predicted, chronic bronchitis, and ≥1 hospitalization for exacerbation in the prior year 1
• Azithromycin 250 mg daily or 500 mg three times weekly in former smokers with frequent exacerbations, acknowledging antimicrobial resistance risk 1, 5

---

Vaccinations

Administer annual influenza vaccine to all COPD patients—it reduces COPD-related mortality by approximately 70% in older adults. 1, 5

• Provide 23-valent pneumococcal vaccine (PPSV23) as part of routine COPD management 1
• For patients ≥65 years, give PCV13 followed by PPSV23 1

---

Pulmonary Rehabilitation

Refer every patient with moderate-to-severe COPD and CAT score ≥10 to comprehensive pulmonary rehabilitation—it improves exercise capacity, reduces dyspnea, enhances quality of life, and lowers hospitalization rates. 4, 1, 5

• Programs should include exercise training, physiotherapy, muscle conditioning, nutritional support, and education 1, 5, 2
• Both obesity and malnutrition require treatment—malnutrition is linked to respiratory-muscle dysfunction and higher mortality 4, 1, 5

---

Long-Term Oxygen Therapy (LTOT)

LTOT prolongs survival and is one of only two interventions proven to reduce mortality in severe COPD (the other being smoking cessation). 4, 1, 5

Prescribe LTOT when arterial PaO₂ ≤55 mmHg (7.3 kPa) on two separate measurements at least three weeks apart, with a target SpO₂ ≥90% during rest, sleep, and exertion. 4, 1, 5

• Do NOT prescribe LTOT for stable COPD with only resting or exercise-induced moderate desaturation 1
• Short-burst (prn) oxygen for breathlessness lacks supporting evidence and should not be used routinely 4, 1

---

Management of Acute Exacerbations

Immediately increase bronchodilator dose/frequency at the onset of an exacerbation. 4, 1, 5

Initiate antibiotics (7-14 day course) if ≥2 of the following are present:

• Increased breathlessness 4, 1, 2
• Increased sputum volume 4, 1, 2
• Development of purulent sputum 4, 1, 2

Prescribe oral prednisone 40 mg daily for 5 days—this improves lung function, shortens recovery time, and reduces early relapse risk; no additional benefit beyond 5-7 days. 1, 5

Hospitalization Criteria

Hospitalize patients with:

• Severe dyspnea 4, 1
• Markedly poor general condition 4, 1
• Current LTOT use 4, 1
• Markedly reduced activity level 4, 1
• Adverse social circumstances 4, 1

Follow-Up After Exacerbation

• Re-evaluate 4-6 weeks after discharge, measuring FEV₁, reviewing inhaler technique, and assessing adherence 4, 1, 5
• If not fully improved in 2 weeks, consider chest radiography and hospital referral 4

---

Advanced Disease Interventions

Non-Invasive Ventilation (NIV)

Offer NIV to patients with chronic severe hypercapnia who have a prior hospitalization for acute respiratory failure—NIV can lower mortality and prevent rehospitalization. 1

Surgical Options

Consider lung-volume-reduction surgery, bullectomy, or lung transplantation for selected patients with advanced emphysema refractory to optimized medical therapy. 4, 1

• Surgery is indicated for recurrent pneumothoraces and isolated bullous disease 4, 1

Palliative Care

Use low-dose, long-acting oral or parenteral opioids to alleviate refractory dyspnea in severe COPD. 1

• Screen for and treat depression, which is common in severe COPD and adversely affects outcomes 4, 1

---

Specialist Referral Indications

Refer to pulmonology for:

• Suspected severe COPD 4, 5
• Onset of cor pulmonale 4
• Assessment for oxygen therapy 4, 5
• COPD in patient <40 years (to identify alpha-1 antitrypsin deficiency) 4
• Rapid decline in FEV₁ 4
• Uncertain diagnosis 4
• Symptoms disproportionate to lung function deficit 4
• Frequent infections (to exclude bronchiectasis) 4

---

Critical Pitfalls to Avoid

Theophyllines have limited efficacy and should NOT be used as first-line therapy. 4, 1, 5

Beta-blocking agents (including eyedrop formulations) must be avoided in all COPD patients. 1, 5

There is no role for anti-inflammatory drugs beyond inhaled corticosteroids in COPD management. 4, 1

Corticosteroid trials must be judged by objective spirometric improvement (≥200 mL AND ≥15% increase); subjective improvement alone is insufficient. 1, 5

Do not prescribe ICS without clear indications (eosinophilia, asthma-COPD overlap, or frequent exacerbations despite dual bronchodilation). 1, 5

Prophylactic or continuous antibiotics lack supporting evidence and should be avoided. 1, 5